Clinical trial · no report yet · Phase 3
EMERALD-1
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
- NCT03778957 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 72 | |
| YouTube | 53 | |
| Podcasts | 34 | |
| Bluesky threads | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab; Bevacizumab; Placebo; Transarterial Chemoembolization (TACE)
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Placebo comparator
- Enrollment
- 724
- Primary outcomes
- Progression Free Survival (PFS) for Arm B vs Arm C
- Sponsor
- AstraZeneca
- Start
- Nov 30, 2018
- Primary completion
- Sep 11, 2023
- Results posted
- No
- Registry record
- NCT03778957 · updated Jul 15, 2026
Publications
linked from the registry- Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Zotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. PubMed 39798579
- Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1:137-149. doi: 10.1002/hep.31424. Epub 2020 Nov 6. No abstract available. PubMed 32557715